James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration.

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.
Evaluation of a potential mutagenic MOA based on analysis of the weight of evidence and using the modified Hill criteria Martha M. Moore, Ph.D. Director,
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
Nonclinical Pharmacology/ Toxicology Data for PROTOPIC  (Tacrolimus ointment for Atopic Dermatitis) Barbara Hill, Ph.D. Division of Dermatologic and Dental.
Ch 5 and 6.1 and 6.2 Cell Division.
Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.
McKim Workshop on Strategic Approaches for Reducing Data Redundancy in Cancer Assessment Jay R. Niemelä Technical University of Denmark National Food Institute.
1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.
JMV 1843 pharmacological profile
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Detecting Mutagens and Carcinogens. introduction - Increased number of chemicals used and present as environmental contaminats, testes for the mutagenicity.
Preclinical – Animal Study
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Human Induced Pluripotent Stem Cells (hiPS Cells)
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA.
Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.
1 11/8/00 Pharmacology of Tacrolimus Ointment William Fitzsimmons, Pharm.D. Vice President Drug Development Project Management Fujisawa Healthcare, Inc.
ILSI Risk Science Institute Acrylamide Toxicity: Research to Address Key Data Gaps Presented by Dr. Stephen S. Olin ILSI Risk Science Institute.
Food and Drug Administration Food and Drug Administration Center for Biologics Evaluation and Research Biological Response Modifiers Advisory Committee.
CVM’s Procedure for Setting Tolerances
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
1.02 Advanced Compliance Strategies for Academic Medical Centers Kenneth L. Dretchen and Shelia Zimmet Georgetown University Medical Center.
28/05/12 Questions (Rispondete alle domande che seguono usando il colore rosso per il testo) Tossicologia - Rubbiani Maristella.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
GENOTOXICITY AND INDUSTRY: UTILIZING GENETIC TOXICITY ASSAYS TO SUPPORT PHARMACEUTICAL DEVELOPMENT August 24, 2015 Dan Roberts, MS Research Scientist Genetic.
Furan in Food Summary and Charge to the FAC and SCNT Terry C. Troxell, Ph.D. Director Office of Plant and Dairy Foods FDA Center for Food Safety and Applied.
1 FDA Review Perspective – Entecavir for Hepatitis B Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products.
False Discovery Rates for Discrete Data Joseph F. Heyse Merck Research Laboratories Graybill Conference June 13, 2008.
CA-1 Preclinical Studies Philip Bentley, PhD Vice President Toxicology/Pathology Novartis Pharmaceuticals Corporation Philip Bentley, PhD Vice President.
Preclinical Guidelines: Development of Radioprotective/Mitigative Agents Departments of Dermatology & Radiation Oncology University of Rochester Medical.
Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.
FAO/WHO Codex Training Package Module 4.3 FAO/WHO CODEX TRAINING PACKAGE SECTION FOUR – SCIENTIFIC BASIS FOR CODEX WORK 4.3 What is JECFA?
Background on Furan in Foods Nega Beru, Ph.D. Director, Division of Plant Product Safety Office of Plant and Dairy Foods Center for Food and Applied Nutrition.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.
Cell Biology: Protein Synthesis Lesson 2 – Mutations( Inquiry into Life pg )
1.Collection of relevant data – toxicity and exposure 2.Selection of critical studies and/or HCVs 3.Health risk assessment – systemic 4.Health risk assessment.
ASTM F748 Selecting Biological Test Methods
1.Collection of relevant data – toxicity and exposure 2.Selection of critical studies and/or HCVs 3.Health risk assessment – systemic 4.Health risk assessment.
Russell D. Owen Wireless Phones Russell D. Owen, Ph.D. Chief, Radiation Biology Branch, Division of Life Sciences CDRH Office of Science and Technology.
European Patients’ Academy on Therapeutic Innovation Non-clinical development.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Furan-Induced Cytotoxicity, Cell Proliferation, and Tumorgenicity in Mouse Liver Dr. Glenda Moser.
The Future of Chemical Toxicity Testing in the U.S.
Pediatric Subcommittee of the AIDAC October 29-30, Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology October 30, 2003 Barbara.
Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.
A UNIQUE IN VIVO ASSAY FOR YOUR ONCOLOGY DRUG CANDIDATES Target Validation Efficacy and Toxicity Evaluation Arnaud Peyronnier Business Development Manager.
Ms. Desirae ORGANIZATION OF THE HUMAN BODY. Plant and Animal  Nucleus: The “brains” of the cell, the nucleus directs cell activities and contains genetic.
Responsible Officer, Volume 112 Monographs Programme
Nonclinical Perspective on Initiating Phase 1 Studies for Biological Oncology Products – Case Studies Anne M. Pilaro, Ph.D. DBOP/OODP/CDER Oncology Drugs.
Summation of Toxicity Data in Vitic Andrew Thresher
(Quantitative) Structure- Activity Relationships (Q)SAR.
Georgetown UNIVERSITY Overview of Gene Transfer as an Evolving Neurotherapeutic Modality Howard J Federoff, MD, PhD Georgetown University Medical Center.
for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.
Patient Focused Drug Development An FDA Perspective
Role of genetic and non-genetic mechanisms in furan risk
FDA Perspective on Cardiovascular Device Development
Biopharmaceutics Dr Mohammad Issa Saleh.
Advisory Committee for Pharmaceutical Science (ACPS)
IND Review Process Seoul National University
Three major barriers to the integration of metagenomics into pharmacology and toxicology. Three major barriers to the integration of metagenomics into.
Note lack of cytotoxicity
Positive Genetox Findings on a Candidate Pharmaceutical…. Now What
Human and Animal Testing: What’s Appropriate
Presentation transcript:

James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration

Entecavir Genetic Toxicity Entecavir is a nucleoside analog, a member of a class of molecules expected to be genetically toxic Mode of action is consistent with its being a mutagen or a clastogen Not an obligate chain terminator It halts DNA synthesis after the addition of a few bases into the growing chain It is clastogenic in vitro in a human lymphocyte assay It is negative in the Ames assay and in a number of in vitro and in vivo genetic toxicology assays. It is negative in the SHE-cell transformation assay

Genetic toxicity Adefovir –Mutagenic in vitro –Induced chromosomal aberrations in vitro Lamivudine –Mutagenic in two in vitro assays Interferon –Not a genetic toxin

Male Rat Tumor Data

Female Rat Tumor Data

Male Mouse Tumor Data

Female Mouse Tumor Data

Carcinogenicity Studies Interferon –No carcinogenicity studies carried out Adefovir –Negative for carcinogenicity –Exposures in studies 10-fold for mice and 4-fold for rats Lamivudine –Negative for carcinogenicity –Exposure in studies 34-fold in mice and 200-fold in rats

Carcinogenicity Assessment Committee CAC founded in the late 1980’s Founded to examine carcinogenicity protocols Also interprets the outcome of carcinogenicity studies Ensures that the assessment of protocols and studies will be consistent among review divisions Two committees exist, an Executive CAC and a Full CAC

Executive CAC –Consists of four members –The Associate Director for the Center –A permanent carcinogenicity expert –Supervisor from the presenting division –A second Pharmacology Supervisor –The Exec CAC meets every Tuesday and reviews from one to four protocols or carcinogenicity studies

Full CAC Reviews studies when the Exec CAC cannot agree or when a drug sponsor makes a request Consists of –The Associate Director of the Center –The three associate Directors for the Offices –The individual Pharmacology Supervisors for the Divisions The Full CAC meets very infrequently

Full CAC Voting Does the CAC agree that the lung tumors in mice are relevant to human safety evaluation? –Yes – 16 No/Probably not – 2 Don’t know – 2 Does the CAC agree that (1) the liver tumors in male mice and (2) the vascular tumors in female mice are relevant to human safety evaluation? –Yes – 17 No – 3 Does the CAC agree that (1) hepatocellular adenomas and carcinomas in female rats, (2) the skin fibromas in female rats and (3) the brain gliomas in male and female rats are relevant to human safety evaluation? –Yes – 17 No - 3

Summary Entecavir is a nucleoside analog which is a genetic toxin Entecavir is carcinogenic in male and female rats and mice Most of the tumors arise at high exposures in the animal studies The carcinogenic effect is relevant to the human safety evaluation Animal findings need to be balanced with the positive outcomes in the clinical trials and the nature of the disease